About Inovio Pharmaceuticals, Inc. (INO)
Inovio Pharmaceuticals (ticker symbol: INO) is a leading American biotechnology company which focuses on the discovery, development, and commercialization of synthetic DNA medicines to treat cancers and infectious diseases The company was first listed on the American Stock Exchange on Dec. 11, 1998, for $59 under its original name, Genetronics. After Genetronics purchased Norway-based Inovio AS in 2005, the company changed its name to Inovio Pharmaceuticals and is now traded under the ticker symbol: INO. Headquartered in Plymouth Meeting, Pennsylvania, United States, Inovio Pharmaceuticals focuses on producing DNA medicines and vaccines to combat infectious diseases, as well as to help treat people with cancer, and conditions associated with human papillomavirus (HPV). The company’s most targeted sectors include healthcare services (50%) and medical products (50%).
As of June 2022, Inovio Pharmaceuticals’ main revenue comes from collaborations and grants. The company has been consistently investing these funds to new DNA research but was slow to produce any results – which in turn led to negative earnings results and a wallowing share price. As previously noted, Inovio Pharmaceuticals’ resulted after the acquisition of Norwegian gene delivery technology company Inovio AS by Genetronics. Inovio Pharmaceuticals’ largest acquisition to date came in 2009, when it acquired VGX Pharmaceuticals for $15M.
Inovio Pharmaceuticals Stock History
In 1998, Genetronics – a company that focused on developing new drug delivery systems using electroporation – launched its IPO on the NASDAQ Stock Exchange. After acquiring Norwegian gene delivery technology company Inovio AS., Genetronics changed its name to Inovio Pharmaceuticals.
In 2007, Inovio’s stock cratered after the company announced that it would halt enrolment in two late-stage clinical studies for squamous cell head and neck cancer investigational therapy. On June 1st, 2009, Inovio Pharmaceuticals merged with VGX Pharmaceuticals, which had famously rolled out a cervical dysplasia vaccine VGX-3100. However, initial excitement among investors about the VGX merger quickly faded after the FDA halted tests on the VGX vaccine, causing Inovio Pharmaceuticals stock to continue on a downward spiral.
In January 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would grant of up to $9 million to Inovio Pharmaceuticals for development of a vaccine against SARS-CoV-2. Despite a promising start to its Covid-19 vaccine research, in May 2022, INO stocks tanked after reports that Inovio Pharmaceuticals’ Chief Executive Officer J. Joseph Kim had resigned from his position following the discontinuation of the company’s Phase III COVID-19 vaccine study. As of June 2022, Inovio Pharmaceuticals has yet to issue any INO stock dividends.
AvaTrade Inovio Pharmaceuticals Stock Trading Information
- Inovio Pharmaceuticals Symbol: #INO
- Trading Times: Monday – Friday 13:00 – 19:59 GMT
- Country: USA
- Currency: USD
- Exchange: NASDAQ
How to Trade Inovio Pharmaceuticals
While Inovio Pharmaceuticals research is ground-breaking to say the least, the company has thus far failed to launch a commercially approved product on the market. However, it is a highly volatile stock, which, for CFD trading, can present some interesting short and long trading opportunities. Here are some factors to consider when trading Inovio Pharmaceuticals stocks:
Breakthroughs, Grants, and Product Launches
Inovio Pharmaceuticals depends heavily on research grants and collaborations to fund its operations. Traders should keep an eye out for research grants as well as FDA announcements regarding Inovio Pharmaceuticals’ research and trials.
Major Milestones & Breakthroughs
New FDA-approved vaccines or DNA medicines by Inovio Pharmaceuticals have the potential to push its stock price significantly higher, while the opposite is true for FDA warnings and trial halts.
The main competitors of Inovio Pharmaceuticals include Immunai, Evotec, Hisamitsu Pharmaceutical and KYORIN Pharmaceutical – but that’s only when it comes to DNA treatments. Other competitors in the race to the world’s first Covid-19 vaccine for example, included medical giants Pfizer and Moderna. Traders should be wary of Inovio Pharmaceuticals’ competitors and the strides they make when it comes to medical research and innovation.
Periodical Earnings Reports
Inovio Pharmaceuticals’ quarterly earnings reports can give traders valuable insights into how the company is faring and provide clues on what the future of the company may look line. Inovio Pharmaceuticals releases quarterly reports at the end of every quarter, with INO’ fiscal year running from December 1st to November 30th of the following year.
Why trade Inovio Pharmaceuticals with AvaTrade
- International Regulation – AvaTrade offers a transparent, regulated, and secure trading environment to clients across the globe.
- Leveraged Trading – AvaTrade gives traders the opportunity to multiply their market exposure and trade Inovio Pharmaceuticals with leverage.
- Ability to Short Sell – AvaTrade supports both Buy and Sell positions with Inovio Pharmaceuticals CFDs, enabling traders to make the most of rising and falling price trends.
- Automated Trading Solutions – Offering limit orders and the option to use trading scripts and EAs on its MetaTrader 4 and 5 platforms, AvaTrade enables traders to fully automate their trading activity.
- Competitive Conditions – AvaTrade features ultra-low trading costs and some the most competitive conditions in the markets, allowing traders to improve their profit margins.
- Exclusive Trading Tools – AvaTrade offers a range of exclusive trading tools including Trading Central, enabling traders to quickly identify potential market opportunities.
- Expert Education & Support – With AvaTrade, traders can access 24/5 dedicated support as well as a wealth of educational resources including live webinars, e-books, and e-courses to help them make better-informed decisions
- Powerful Trading Platforms – AvaTrade features a range of leading trading platforms including the MT4, the MT5 and AvaTradeGo.
See a trading opportunity? Open an account now!